New York
…Floor New York, NY 10032 212-305-5098 cumc.columbia.edu Benjamin Izar, MD Mirian El-Ashwamy, MD Memorial Sloan-Kettering Cancer Center * Melanoma Disease…
New York
…Floor New York, NY 10032 212-305-5098 cumc.columbia.edu Benjamin Izar, MD Mirian El-Ashwamy, MD Memorial Sloan-Kettering Cancer Center * Melanoma Disease…
Palliative Care
…of life for both the patient and the family. Many melanoma patients experience side effects from their treatment that can…
Michigan
[aim_melanoma_specialist] Find a Specialist University of Michigan Rogel Comprehensive Cancer Center 1500 East Medical Center Drive Ann Arbor, MI 48109 734-936-4068 https://www.rogelcancercenter.org/skin-cancer/melanoma/advanced-melanoma…
New Jersey
[aim_melanoma_specialist] Find a Specialist Saint Barnabas Medical Center 94 Old Short Hills Road Livingston NJ 07039 973-322-6515 barnabashealth.org Michael Scoppetuolo,…
Ultraviolet (UV) Radiation
…of melanoma and other skin cancers such as basal cell carcinoma and squamous cell carcinoma. The sun’s UV rays can…
Skin Biopsy: The First Step
…from the site of the surgery. Superficial Shave Biopsies are DISCOURAGED for suspected melanomas other than melanoma in situ. Suspected…
UPMC Hillman Cancer Center | March 13
…10:45 AM ET Microbiome Modulation in Advanced Refractory Melanoma Diwakar Davar, MD Assistant Professor of Medicine UPMC Hillman Cancer Center…
Sarah Cannon | Sept. 30
…presentation Presenters & Topics 5:30 PM ET Opening Remarks Samantha Guild President AIM at Melanoma Foundation 5:35 PM ET Welcome and Introductions…
Moffitt Cancer Center | March 4, 2023
… What’s the Best Approach to Treating Stage IV Melanoma? Lilit Karapetyan, MD, MS, FACP Moffitt Cancer Center The…
Finding a Clinical Trial
How do you find a melanoma clinical trial? In partnership with EmergingMed, AIM at Melanoma provides phone and web-based pre-screening,…
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026